What Is Ketamine-Assisted Psychotherapy (KAP)?

Ketamine-assisted psychotherapy, or KAP, combines ketamine with psychotherapy in a clinically supported treatment process.

Rather than viewing ketamine as an isolated intervention, KAP typically incorporates preparation before the medicine experience and therapeutic integration afterward.

Interest in this approach has grown alongside research showing that ketamine can produce unusually rapid antidepressant effects in some people. Researchers are also studying whether the temporary changes in brain function, perception, and cognitive flexibility associated with ketamine may create a useful period for therapeutic work.

The science is promising—but it is also important to distinguish what researchers know about ketamine itself from what they are still learning about ketamine-assisted psychotherapy as a combined treatment.

A Brief History of Ketamine

Ketamine has been used in medicine as an anesthetic for decades.

Its potential psychiatric effects began attracting major scientific attention after researchers found that subanesthetic intravenous ketamine could reduce depressive symptoms much more rapidly than conventional antidepressant medications in some people with treatment-resistant depression.

NIMH-supported research helped establish that antidepressant effects can emerge within hours rather than the weeks typically associated with many conventional antidepressants.

Ketamine's psychiatric use remains off-label in the United States. FDA-approved ketamine products are approved as anesthetics, not for psychiatric disorders.

What Happens in the Brain?

The biology of ketamine is complex, and scientists do not believe there is one simple mechanism.

One of the most important differences between ketamine and conventional antidepressants involves glutamate, the brain's major excitatory neurotransmitter.

Ketamine interacts with glutamate signaling by blocking NMDA receptors. Researchers believe downstream changes can increase activity at another type of glutamate receptor called the AMPA receptor and influence molecular pathways involved in synaptic function and neuroplasticity.

What Is Neuroplasticity?

Neuroplasticity is the brain's ability to alter and reorganize connections between neurons in response to experience.

A systematic review examining ketamine and molecular neuroplasticity identified changes involving glutamate, AMPA receptors, BDNF, mTOR, and other signaling systems associated with neural plasticity. However, many details of how these molecular changes translate into clinical improvement in humans remain under investigation.

You may sometimes hear this simplified as ketamine “rewiring the brain.” That is an appealing phrase, but it is more accurate to say that ketamine appears to influence biological processes involved in synaptic plasticity and adaptability.

Why Combine Ketamine With Psychotherapy?

This is where KAP differs from medication-only models.

Some researchers have proposed that the period surrounding ketamine treatment may involve increased psychological flexibility, altered emotional processing, different perspectives on familiar experiences, or greater openness to therapeutic material.

If ketamine temporarily creates a state in which familiar patterns feel less rigid, psychotherapy may offer a structured way to work with that experience.

This idea is scientifically plausible, but it is still being tested.

A 2023 systematic review examined 19 studies totaling 1,006 patients who received ketamine combined with psychotherapy. The results were largely positive, but the studies differed considerably in diagnoses, psychotherapy methods, ketamine protocols, and timing. Researchers concluded that KAP appears promising while emphasizing that larger randomized controlled trials are needed to determine how psychotherapy should best be integrated with ketamine treatment.

That distinction matters. We have substantial research showing ketamine itself can have rapid psychiatric effects. The evidence establishing the added benefit and ideal structure of psychotherapy around ketamine is newer and less standardized.

What Are Preparation and Integration?

Preparation takes place before the ketamine experience.

This may involve discussing expectations, treatment goals, concerns, safety, and how to respond to unfamiliar sensations or emotions during the session. Preparation can also help establish trust between a patient and treatment team.

Integration occurs after the ketamine experience.

People may emerge from a session with emotions, memories, insights, questions, or new ways of viewing familiar problems. Integration provides a structured opportunity to explore those experiences and consider how they might connect with ongoing therapy and everyday life.

One reason integration is emphasized is that the subjective experience alone does not automatically create lasting behavioral change.

The therapeutic work is about what happens before, during, and after the medicine experience.

What Does a Ketamine Experience Feel Like?

Experiences vary widely.

People may notice changes in perception, time, body awareness, emotions, thoughts, memories, or their usual sense of self. Dissociation—feeling temporarily detached from one's body, surroundings, or usual perspective—is also a known effect of ketamine.

These effects are among the reasons appropriate screening, dosing, monitoring, and clinical support matter.

Ketamine can also temporarily increase blood pressure and has potential for misuse, which is another reason medical oversight is important. FDA safety information regarding ketamine and esketamine highlights risks including sedation, dissociation, cardiovascular effects, respiratory concerns in certain settings, and abuse or misuse potential.

What Conditions Is Ketamine Being Studied For?

The strongest psychiatric evidence for ketamine is associated with depression, particularly difficult-to-treat depression.

Research has also explored ketamine in areas including PTSD, substance use disorders, anxiety-related conditions, and other psychiatric concerns. Research specifically combining ketamine with psychotherapy has included several different diagnostic populations, but results should not be interpreted to mean KAP has been established as a proven treatment for every condition studied.

Treatment decisions should always be based on an individual's clinical history and an appropriate evaluation.

Is KAP a Quick Fix?

No.

One of the most interesting things about ketamine is how quickly biological or symptomatic changes may occur in some people. But rapid change in symptoms is not the same thing as lasting psychological change.

KAP approaches the medicine experience as one part of a larger therapeutic process.

Preparation, clinical support, integration, ongoing psychotherapy when appropriate, and changes made in daily life may all matter in determining what someone ultimately takes away from treatment.

Ketamine-Assisted Psychotherapy at Awaken

Awaken Mental Health offers ketamine-assisted psychotherapy in Portland, Maine within a broader model of mental health care that includes psychotherapy and psychiatric services.

Our focus is on thoughtful clinical evaluation, safety, preparation, support, and integration rather than treating ketamine as a standalone experience.

If you are wondering whether KAP may be appropriate for you, the first step is a clinical conversation about your symptoms, health history, previous treatment, goals, and questions. It is offered in individual and group settings based on your needs.

Learn More About Ketamine Therapy in Portland, Maine →

References

Joneborg M, et al. Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review. BJPsych Open. 2023. The review evaluated 19 studies involving 1,006 patients.

Kang MJY, Hawken E, Vazquez GH. The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity. Frontiers in Psychiatry. 2022.

National Institute of Mental Health. Cracking the Ketamine Code. 2023.

National Institute of Mental Health. New Hope for Rapid-Acting Depression Treatment. 2024.

U.S. Food and Drug Administration. Current ketamine and esketamine regulatory and safety information.